You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSirolimus
Accession NumberDB00877  (APRD00178, DB02439)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to immunophilins. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties. [PubChem]
Structure
Thumb
Synonyms
(-)-Rapamycin
Rapamycin
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Gd-sirolimusTablet2 mgOralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-sirolimusTablet5 mgOralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-sirolimusSolution1.0 mgOralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-sirolimusTablet1.0 mgOralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
RapamuneTablet, sugar coated1 mg/1OralCardinal Health2001-07-01Not applicableUs
RapamuneTablet, coated0.5 mgOralPfizer2001-03-13Not applicableEu
RapamuneTablet, coated1 mgOralPfizer2001-03-13Not applicableEu
RapamuneTablet5 mgOralPfizerNot applicableNot applicableCanada
RapamuneTablet, sugar coated2 mg/1OralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2001-07-01Not applicableUs
RapamuneSolution1 mg/mLOralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.1999-09-01Not applicableUs
RapamuneTablet, coated2 mgOralPfizer2001-03-13Not applicableEu
RapamuneSolution1 mg/mlOralPfizer2001-03-13Not applicableEu
RapamuneTablet1.0 mgOralPfizer2003-03-25Not applicableCanada
RapamuneTablet, sugar coated.5 mg/1OralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2010-03-01Not applicableUs
RapamuneTablet, coated2 mgOralPfizer2001-03-13Not applicableEu
RapamuneTablet, coated1 mgOralPfizer2001-03-13Not applicableEu
RapamuneTablet2 mgOralPfizerNot applicableNot applicableCanada
RapamuneTablet, sugar coated1 mg/1OralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2001-07-01Not applicableUs
RapamuneTablet, coated0.5 mgOralPfizer2001-03-13Not applicableEu
Rapamune Oral SolutionSolution1.0 mgOralPfizer2001-05-15Not applicableCanada
SirolimusTablet, sugar coated2 mg/1OralGreenstone, Llc2014-10-27Not applicableUs
SirolimusTablet, sugar coated.5 mg/1OralGreenstone, Llc2014-01-07Not applicableUs
SirolimusTablet, sugar coated1 mg/1OralGreenstone, Llc2014-10-27Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SirolimusTablet1 mg/1OralDr Reddy's Laboratories2014-10-27Not applicableUs
SirolimusTablet, film coated.5 mg/1OralAmerincan Health Packaging2015-03-31Not applicableUs
SirolimusTablet2 mg/1OralDr Reddy's Laboratories2014-10-27Not applicableUs
SirolimusTablet, film coated.5 mg/1OralZydus Pharmaceuticals Usa, Inc.2014-01-15Not applicableUs
SirolimusTablet, film coated.5 mg/1OralCadila Pharnmaceuticals2014-01-15Not applicableUs
SirolimusTablet1 mg/1OralAmerincan Health Packaging2015-10-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIW36ZG6FT64
CAS number53123-88-9
WeightAverage: 914.1719
Monoisotopic: 913.555141619
Chemical FormulaC51H79NO13
InChI KeyQFJCIRLUMZQUOT-KLHQEZAJSA-N
InChI
InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33+,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
IUPAC Name
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
SMILES
[H][C@@]1(C[[email protected]](C)[C@]2([H])CC(=O)[[email protected]](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[[email protected]](C)C[[email protected]](C)\C=C\C=C\C=C(C)\[[email protected]](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC
Pharmacology
IndicationFor the prophylaxis of organ rejection in patients receiving renal transplants.
Structured Indications
PharmacodynamicsSirolimus, a macrocyclic lactone produced by Streptomyces hygroscopicus, is an immunosuppressive agent indicated for the prophylaxis of organ rejection in patients receiving renal transplants. It is recommended that sirolimus be used in a regimen with cyclosporine and corticosteroids.
Mechanism of actionSirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.
TargetKindPharmacological actionActionsOrganismUniProt ID
Serine/threonine-protein kinase mTORProteinyes
inhibitor
HumanP42345 details
Peptidyl-prolyl cis-trans isomerase FKBP1AProteinyes
other
HumanP62942 details
Fibroblast growth factor 2Proteinyes
other/unknown
HumanP09038 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding92%
Metabolism
SubstrateEnzymesProduct
Sirolimus
41-O-demethylrapamycinDetails
Route of eliminationNot Available
Half life57-63 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Sirolimus.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Sirolimus.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Sirolimus.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Sirolimus.Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Sirolimus.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Sirolimus.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Sirolimus.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Sirolimus.Experimental
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Sirolimus.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Sirolimus.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Sirolimus.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Sirolimus.Approved, Investigational
AmiodaroneThe metabolism of Sirolimus can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Sirolimus.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Sirolimus.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Sirolimus is combined with Amrinone.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Sirolimus.Approved
AprepitantThe serum concentration of Sirolimus can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Sirolimus.Approved, Investigational
AtazanavirThe metabolism of Sirolimus can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Sirolimus.Approved
AtomoxetineThe metabolism of Sirolimus can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Sirolimus.Approved, Investigational
AzelnidipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Azelnidipine.Approved
AzimilideThe risk or severity of adverse effects can be increased when Sirolimus is combined with Azimilide.Investigational
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Sirolimus.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Barnidipine.Approved
BCGThe therapeutic efficacy of Bcg can be decreased when used in combination with Sirolimus.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Benazepril.Approved, Investigational
BenidipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Benidipine.Approved
BepridilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Sirolimus.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Sirolimus.Approved, Investigational
BexaroteneThe serum concentration of Sirolimus can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe serum concentration of Sirolimus can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Sirolimus can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Sirolimus can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Sirolimus.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Sirolimus.Approved
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Sirolimus.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Sirolimus.Withdrawn
BuspironeThe metabolism of Buspirone can be decreased when combined with Sirolimus.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Sirolimus.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sirolimus.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Sirolimus.Approved
CaiThe risk or severity of adverse effects can be increased when Sirolimus is combined with Cai.Investigational
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Sirolimus.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Sirolimus.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Captopril.Approved
CarbamazepineThe metabolism of Sirolimus can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe metabolism of Sirolimus can be decreased when combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Sirolimus.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Sirolimus.Experimental
CeritinibThe serum concentration of Sirolimus can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Sirolimus.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Sirolimus.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Sirolimus.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Sirolimus.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Sirolimus.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Cinnarizine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Sirolimus.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Sirolimus.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Sirolimus.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Sirolimus.Approved
ClarithromycinThe metabolism of Sirolimus can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Sirolimus can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Sirolimus.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Sirolimus.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Sirolimus.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Sirolimus.Approved, Nutraceutical
ClotrimazoleThe metabolism of Sirolimus can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClotrimazoleThe serum concentration of Sirolimus can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Clozapine.Approved
CobicistatThe metabolism of Sirolimus can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Sirolimus.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Sirolimus.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Sirolimus.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Sirolimus.Approved
CrizotinibThe serum concentration of Sirolimus can be increased when it is combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Sirolimus.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Sirolimus can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Sirolimus.Approved
DabrafenibThe serum concentration of Sirolimus can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Sirolimus.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Sirolimus.Approved
DarodipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Darodipine.Experimental
DarunavirThe metabolism of Sirolimus can be decreased when combined with Darunavir.Approved
DasabuvirThe serum concentration of Sirolimus can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Sirolimus can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Sirolimus.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Sirolimus.Approved
DeferasiroxThe serum concentration of Sirolimus can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Sirolimus can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Sirolimus.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Sirolimus.Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Sirolimus.Approved
DexamethasoneThe serum concentration of Sirolimus can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Sirolimus.Approved, Illicit, Vet Approved
DidanosineDidanosine can cause a decrease in the absorption of Sirolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Sirolimus.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Sirolimus.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Sirolimus.Approved
DihydroergotamineThe metabolism of Sirolimus can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Sirolimus.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Sirolimus is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Sirolimus.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Sirolimus.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Sirolimus.Approved
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Sirolimus.Approved, Investigational, Vet Approved
DotarizineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Dotarizine.Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Sirolimus.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Sirolimus.Approved, Investigational
DoxycyclineThe metabolism of Sirolimus can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Sirolimus can be decreased when combined with Dronedarone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Sirolimus.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Sirolimus.Approved
EfavirenzThe serum concentration of Sirolimus can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Sirolimus.Approved, Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Sirolimus.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Sirolimus is combined with Enalaprilat.Approved
EnzalutamideThe serum concentration of Sirolimus can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Sirolimus is combined with Eperisone.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Sirolimus.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Sirolimus.Approved, Investigational
ErythromycinThe metabolism of Sirolimus can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Sirolimus can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Sirolimus.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Sirolimus.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Sirolimus.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Sirolimus.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Sirolimus.Approved
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Sirolimus.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Sirolimus.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Sirolimus.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Sirolimus.Approved
FelodipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Fendiline.Withdrawn
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Sirolimus.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Sirolimus.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Sirolimus.Approved
FingolimodSirolimus may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of Sirolimus can be increased when it is combined with Fluconazole.Approved
FlunarizineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Flunarizine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Sirolimus.Approved
FluvoxamineThe metabolism of Sirolimus can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Sirolimus can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Sirolimus can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Sirolimus can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Sirolimus can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Sirolimus is combined with G17DT.Investigational
GabapentinThe risk or severity of adverse effects can be increased when Sirolimus is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Gallopamil.Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Sirolimus.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Sirolimus.Approved
GI-5005The risk or severity of adverse effects can be increased when Sirolimus is combined with GI-5005.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Sirolimus.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Sirolimus.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Sirolimus.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Sirolimus.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Sirolimus.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Sirolimus.Approved
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Sirolimus.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Sirolimus.Withdrawn
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Sirolimus.Investigational
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Sirolimus.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Sirolimus.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Sirolimus.Approved
IdelalisibThe serum concentration of Sirolimus can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Sirolimus can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Sirolimus.Approved
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Sirolimus.Approved
IndinavirThe metabolism of Sirolimus can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Sirolimus.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Sirolimus is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Sirolimus is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Sirolimus.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Sirolimus.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Sirolimus.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Sirolimus.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Sirolimus.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Sirolimus.Approved
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Sirolimus.Approved, Investigational
IsavuconazoniumThe metabolism of Sirolimus can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Sirolimus can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Sirolimus can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Sirolimus.Approved, Vet Approved
JosamycinThe metabolism of Sirolimus can be decreased when combined with Josamycin.Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Sirolimus.Approved
KetoconazoleThe serum concentration of Sirolimus can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Sirolimus can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Sirolimus can be decreased when combined with Kitasamycin.Experimental
LacidipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Sirolimus.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Lamotrigine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Sirolimus.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Sirolimus.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Sirolimus is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Sirolimus.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Sirolimus.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Sirolimus.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Sirolimus.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Sirolimus.Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Sirolimus.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Sirolimus.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Lisinopril.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Sirolimus.Approved
LopinavirThe metabolism of Sirolimus can be decreased when combined with Lopinavir.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Sirolimus.Approved
LovastatinThe metabolism of Sirolimus can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Sirolimus can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Sirolimus can be increased when combined with Lumacaftor.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Sirolimus is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Manidipine.Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Sirolimus.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Sirolimus.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Sirolimus.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Sirolimus.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Sirolimus.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Sirolimus.Approved, Investigational
MibefradilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Sirolimus.Approved, Illicit
MifepristoneThe serum concentration of Sirolimus can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Sirolimus.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Sirolimus.Approved
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Sirolimus.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Sirolimus.Approved, Investigational
MitotaneThe serum concentration of Sirolimus can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Sirolimus.Approved, Investigational
ModafinilThe serum concentration of Sirolimus can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Moexipril.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Sirolimus.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Sirolimus.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Sirolimus.Approved
NafcillinThe serum concentration of Sirolimus can be decreased when it is combined with Nafcillin.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Sirolimus.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Sirolimus.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Sirolimus is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Sirolimus.Approved, Investigational
NefazodoneThe metabolism of Sirolimus can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Sirolimus can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Sirolimus can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Sirolimus can be increased when combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Niguldipine.Experimental
NilotinibThe metabolism of Sirolimus can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nimodipine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Sirolimus.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nitrendipine.Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Sirolimus.Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Sirolimus.Approved, Investigational
OlaparibThe metabolism of Sirolimus can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Sirolimus can be decreased when combined with Oleandomycin.Vet Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Sirolimus.Experimental
OmapatrilatThe risk or severity of adverse effects can be increased when Sirolimus is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Sirolimus can be increased when it is combined with Ombitasvir.Approved
OsimertinibThe serum concentration of Sirolimus can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Sirolimus.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sirolimus.Approved, Vet Approved
PalbociclibThe serum concentration of Sirolimus can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Sirolimus.Approved, Investigational
ParitaprevirThe serum concentration of Sirolimus can be increased when it is combined with Paritaprevir.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Sirolimus.Approved
PentobarbitalThe metabolism of Sirolimus can be increased when combined with Pentobarbital.Approved, Vet Approved
PerhexilineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Perhexiline.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Perindopril.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Sirolimus.Approved, Withdrawn
PhenobarbitalThe metabolism of Sirolimus can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Sirolimus can be decreased when it is combined with Phenytoin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sirolimus.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sirolimus.Approved, Investigational
PimozideSirolimus may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Sirolimus is combined with Pinaverium.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Sirolimus.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Sirolimus.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Sirolimus.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Sirolimus.Approved
PosaconazoleThe serum concentration of Sirolimus can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Sirolimus.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Sirolimus.Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Sirolimus.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Sirolimus.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Sirolimus.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Sirolimus is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Prenylamine.Withdrawn
PrimidoneThe metabolism of Sirolimus can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Sirolimus.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Sirolimus.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Sirolimus.Approved
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Sirolimus.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Quinidine can be decreased when combined with Sirolimus.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Sirolimus.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Sirolimus.Approved
RamiprilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Ramipril.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Sirolimus.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Sirolimus.Approved, Investigational
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Sirolimus.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Rescinnamine.Approved
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Sirolimus.Approved
RifabutinThe metabolism of Sirolimus can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Sirolimus can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Sirolimus can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Sirolimus.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Sirolimus is combined with CDX-110.Investigational
RisedronateThe risk or severity of adverse effects can be increased when Sirolimus is combined with Risedronate.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Sirolimus.Approved, Investigational
RitonavirThe serum concentration of Sirolimus can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Sirolimus.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Sirolimus.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Sirolimus.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Sirolimus.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Sirolimus.Approved, Vet Approved
SaquinavirThe metabolism of Sirolimus can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Sirolimus.Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Sirolimus.Approved
SildenafilThe metabolism of Sirolimus can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Sirolimus.Approved
SiltuximabThe serum concentration of Sirolimus can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Sirolimus can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Sirolimus.Approved
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Sirolimus.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Sirolimus.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Sirolimus.Approved
SolithromycinThe metabolism of Sirolimus can be decreased when combined with Solithromycin.Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Sirolimus.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Sirolimus.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Sirolimus.Experimental
SpiraprilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Spirapril.Approved
SRP 299The risk or severity of adverse effects can be increased when Sirolimus is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Sirolimus can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Sirolimus can be increased when it is combined with Stiripentol.Approved
SucralfateSucralfate can cause a decrease in the absorption of Sirolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulfisoxazoleThe metabolism of Sirolimus can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Sirolimus.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Sirolimus.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Sirolimus.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Sirolimus.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Sirolimus.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Sirolimus.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Sirolimus.Approved
TelaprevirThe serum concentration of Sirolimus can be increased when it is combined with Telaprevir.Approved
TelithromycinThe metabolism of Sirolimus can be decreased when combined with Telithromycin.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Sirolimus.Approved
TG4010The risk or severity of adverse effects can be increased when Sirolimus is combined with TG4010.Investigational
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Sirolimus.Investigational
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Sirolimus.Approved
TiclopidineThe metabolism of Sirolimus can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Sirolimus.Approved
TocilizumabThe serum concentration of Sirolimus can be decreased when it is combined with Tocilizumab.Approved
TofacitinibSirolimus may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Sirolimus.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Sirolimus.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Sirolimus is combined with Tolfenamic Acid.Approved
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Sirolimus.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Sirolimus.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Sirolimus.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Sirolimus is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Sirolimus.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Sirolimus.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Sirolimus.Withdrawn
TroleandomycinThe metabolism of Sirolimus can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Sirolimus can be decreased when combined with Tylosin.Vet Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Sirolimus.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Sirolimus.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Sirolimus.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Sirolimus.Approved
VenlafaxineThe metabolism of Sirolimus can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Sirolimus is combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Sirolimus.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Sirolimus.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Sirolimus.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Sirolimus.Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Sirolimus.Approved, Investigational
VoriconazoleThe serum concentration of Sirolimus can be increased when it is combined with Voriconazole.Approved, Investigational
XylometazolineThe risk or severity of adverse effects can be increased when Sirolimus is combined with Xylometazoline.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Sirolimus is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Sirolimus.Approved
ZiprasidoneThe metabolism of Sirolimus can be decreased when combined with Ziprasidone.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Sirolimus.Approved
Food InteractionsNot Available
References
Synthesis Reference

Madhup K. Dhaon, Chi-nung Hsiao, Subhash R. Patel, Peter J. Bonk, Sanjay R. Chemburkar, Yong Y. Chen, “One pot synthesis of tetrazole derivatives of sirolimus.” U.S. Patent US20080167335, issued July 10, 2008.

US20080167335
General References
  1. Pritchard DI: Sourcing a chemical succession for cyclosporin from parasites and human pathogens. Drug Discov Today. 2005 May 15;10(10):688-91. [PubMed:15896681 ]
  2. Shuchman M: Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med. 2006 Nov 9;355(19):1949-52. [PubMed:17093244 ]
  3. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005 Aug 15;65(16):7052-8. [PubMed:16103051 ]
  4. Chan S: Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer. 2004 Oct 18;91(8):1420-4. [PubMed:15365568 ]
  5. Graziani EI: Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs. Nat Prod Rep. 2009 May;26(5):602-9. doi: 10.1039/b804602f. Epub 2009 Mar 5. [PubMed:19387497 ]
External Links
ATC CodesS01XA23L04AA10
AHFS Codes
  • 92:00.00
PDB Entries
FDA labelDownload (480 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentAcute Kidney Injury (AKI)1
0CompletedTreatmentInvasive Bladder Cancer Stage II1
0CompletedTreatmentMyelomas1
0CompletedTreatmentTransplantation, Stem Cell1
0CompletedTreatmentTumors, Solid1
0RecruitingTreatmentBladder Cancers1
0RecruitingTreatmentSickle Cells Disease1
0TerminatedTreatmentPemphigus1
1Active Not RecruitingTreatmentAstrocytomas / Atypical Teratoid/Rhabdoid Tumor / Clear Cell Sarcoma of Soft Tissue / Ependymomas / Germ Cell Tumors / Gliomas / Hepatoblastomas / Medulloblastomas / Neuroblastomas / Osteosarcomas / Renal Cell Carcinoma (RCC) / Retinoblastoma / Rhabdoid Tumors / Rhabdomyosarcomas / Sarcoma, Ewing's / Wilms Tumor1
1Active Not RecruitingTreatmentCancer of Kidney / Cancer of Liver / Lymphoma NOS / Neoplasms, Breast / Neoplasms, Lung1
1Active Not RecruitingTreatmentCancer, Advanced1
1Active Not RecruitingTreatmentChildhood Solid Tumors / Malignant Solid Tumors1
1Active Not RecruitingTreatmentRecurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Cavity Cancer / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Epithelial Cancer / Stage IIA Primary Peritoneal Cavity Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Epithelial Cancer / Stage IIB Primary Peritoneal Cavity Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Epithelial Cancer / Stage IIC Primary Peritoneal Cavity Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Epithelial Cancer / Stage IIIA Primary Peritoneal Cavity Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Epithelial Cancer / Stage IIIB Primary Peritoneal Cavity Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Epithelial Cancer / Stage IIIC Primary Peritoneal Cavity Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Primary Peritoneal Cavity Cancer1
1Active Not RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1CompletedNot AvailableAcute Lymphoblastic Leukaemias (ALL)1
1CompletedNot AvailableAdvanced Solid Tumors / Refractory to Standard Therapies1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Isavuconazole / Pharmacokinetics of Sirolimus1
1CompletedBasic ScienceDrug Interactions / Hypercholesterolaemia / Immunosuppression / Pharmacokinetics1
1CompletedPreventionImmunosuppression / Kidney Failure,Chronic / Transplantation, Kidney1
1CompletedPreventionNeoplastic Syndrome / Non-Melanomatous Skin Cancer1
1CompletedTreatmentAML / CML / Leukemias / Myeloid Leukemias1
1CompletedTreatmentAcute Myeloid Leukaemias (AML)1
1CompletedTreatmentAdvanced Cancers1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAging / CAD1
1CompletedTreatmentAllogeneic Stem Cell Transplantation / Malignancies, Hematologic1
1CompletedTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligoastrocytoma / Anaplastic Oligodendroglioma (AO) / Estrogen Receptor Negative / Estrogen Receptor Positive / Glioblastomas / Hormone-Resistant Prostate Cancer / Metastatic Prostate Carcinoma / Metastatic Renal Cell Cancer / Recurrent Adult Brain Neoplasm / Recurrent Bladder Carcinoma / Recurrent Breast Carcinoma / Recurrent Colorectal Carcinoma / Recurrent Esophageal Carcinoma / Recurrent Gastric Carcinoma / Recurrent Hepatocellular Carcinoma / Recurrent Lung Carcinoma / Recurrent Melanoma / Recurrent Ovarian Carcinoma / Recurrent Prostate Carcinoma / Recurrent Renal Cell Carcinoma / Recurrent Uterine Corpus Carcinoma / Resectable Hepatocellular Carcinoma / Sarcomas / Stage IA Breast Cancer / Stage IA Ovarian Cancer / Stage IA Uterine Corpus Cancer / Stage IB Breast Cancer / Stage IB Ovarian Cancer / Stage IB Uterine Corpus Cancer / Stage IC Ovarian Cancer / Stage II Uterine Corpus Cancer / Stage IIA Breast Cancer / Stage IIA Lung Carcinoma / Stage IIA Ovarian Cancer / Stage IIB Breast Cancer / Stage IIB Esophageal Cancer / Stage IIB Lung Carcinoma / Stage IIB Ovarian Cancer / Stage IIB Skin Melanoma / Stage IIC Ovarian Cancer / Stage IIC Skin Melanoma / Stage IIIA Breast Cancer / Stage IIIA Esophageal Cancer / Stage IIIA Lung Carcinoma / Stage IIIA Ovarian Cancer / Stage IIIA Skin Melanoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Breast Cancer / Stage IIIB Esophageal Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Skin Melanoma / Stage IIIB Uterine Corpus Cancer / Stage IIIC Breast Cancer / Stage IIIC Esophageal Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Skin Melanoma / Stage IIIC Uterine Corpus Cancer / Stage IV Bladder Urothelial Carcinoma / Stage IV Esophageal Cancer / Stage IV Ovarian Cancer / Stage IV Prostate Cancer / Stage IV Skin Melanoma / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
1CompletedTreatmentBrain and Central Nervous System Tumors1
1CompletedTreatmentCancer, Advanced4
1CompletedTreatmentCancer, Advanced / Metastatic Cancers1
1CompletedTreatmentDiabetes Mellitus, Type 11
1CompletedTreatmentDiabetic Macular Edema (DME) / Retinopathy, Diabetic1
1CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Multiple Myeloma and Plasma Cell Neoplasm1
1CompletedTreatmentFacial Angiofibroma1
1CompletedTreatmentGlioblastomas1
1CompletedTreatmentGraft Versus Host Disease (GVHD) / Peripheral Blood Stem Cell Transplantation / Transplantation, Homologous1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHepatic Complications1
1CompletedTreatmentHepatocellular Carcinomas / Rapamycin1
1CompletedTreatmentKidney Diseases1
1CompletedTreatmentLeukemias / Lymphoma NOS / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Plasma Cell Neoplasms1
1CompletedTreatmentLiver Cancer1
1CompletedTreatmentLow-Grade Gliomas1
1CompletedTreatmentLymphangioleiomyomatosis1
1CompletedTreatmentNeoplasms Metastasis / Tumors1
1CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
1CompletedTreatmentPachyonychia Congenita1
1CompletedTreatmentRejection, Transplant / Transplantation, Renal1
1CompletedTreatmentSarcomas1
1CompletedTreatmentTumors, Central Nervous System / Tumors, Solid1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentUveitis, Anterior1
1Not Yet RecruitingTreatmentPompe's Disease1
1Not Yet RecruitingTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer1
1RecruitingTreatmentAdvanced Cancers1
1RecruitingTreatmentClear Cell Carcinoma / Gastrointestinal Tumors / Germ Cell Tumors / Hepatic Tumors / Lymphoma NOS / Melanoma / Neuroblastomas / Non-rhabdomyosarcoma / Renal Cell Carcinoma (RCC) / Rhabdoid Tumors / Rhabdomyosarcomas / Sarcoma, Ewing's / Wilms Tumor1
1RecruitingTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma1
1RecruitingTreatmentSickle Cell-thalassemia Disease / Thalassemias1
1SuspendedTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentAdvanced Solid Cancers1
1TerminatedTreatmentEosinophilic Esophagitis / Eosinophilic Gastroenteritis1
1TerminatedTreatmentLeukemias / Lymphoma NOS1
1TerminatedTreatmentLeukemias / Lymphoma NOS / Myelomas1
1TerminatedTreatmentLeukemias / Lymphoma, Hodgkins / MDS / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
1TerminatedTreatmentTumors1
1Unknown StatusTreatmentCardiac Hypertrophy / Immunosuppression1
1Unknown StatusTreatmentDiffuse posterior uveitis / Panuveitis / Uveitis / Uveitis, Intermediate1
1Unknown StatusTreatmentRefractory Solid Tumors in Children1
1WithdrawnSupportive CareAcute Myeloid Leukemia in Remission / Primary Myelofibrosis / Primary Myelofibrosis, Prefibrotic Stage / Secondary Acute Myeloid Leukemia / Secondary Myelofibrosis1
1WithdrawnTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1WithdrawnTreatmentRecurrent Non-small Cell Lung Cancer / Squamous Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1WithdrawnTreatmentRecurrent Non-small Cell Lung Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentAlemtuzumab (Campath ) / Graft Versus Host Disease (GVHD) / Peripheral Blood Stem Cell Transplantation / Sickle Cell Anemia / Sirolimus (Rapamune )1
1, 2Active Not RecruitingTreatmentAnemia, Hemolytic, Autoimmune / Autoimmune Lymphoproliferative Syndrome (ALPS) / Autoimmune Neutropenia / Autoimmune Pancytopenia / Evans Syndrome / Idiopathic Thrombocytopenic Purpura (ITP) / Inflammatory Bowel Diseases (IBD) / Lupus Erythematosus, Systemic / Rheumatoid Arthritis1
1, 2Active Not RecruitingTreatmentMalignant Peripheral Nerve Sheath Tumors (MPNST) / Sarcomas1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1, 2Active Not RecruitingTreatmentRectum Cancer1
1, 2Active Not RecruitingTreatmentRecurrent Bladder Carcinoma / Stage II Bladder Cancer / Stage III Bladder Cancer / Stage IV Bladder Cancer1
1, 2CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2CompletedTreatmentAdvanced Soft Tissue Sarcoma1
1, 2CompletedTreatmentAge-Related Macular Degeneration (ARMD)1
1, 2CompletedTreatmentAge-Related Macular Degeneration (ARMD) / Geographic Atrophy1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors1
1, 2CompletedTreatmentCNI Side Effects1
1, 2CompletedTreatmentGraft Versus Host Disease (GVHD)1
1, 2CompletedTreatmentHypoglycemia / Type 1 Diabetes Mellitus (T1DM)1
1, 2CompletedTreatmentKidney Diseases / Kidney Failure / Transplantation, Kidney1
1, 2CompletedTreatmentKidney Diseases / Transplantation, Kidney1
1, 2CompletedTreatmentMouth Neoplasms / Neoplasms, Head and Neck / Squamous Cell Carcinoma (SCC) / Tongue Neoplasms1
1, 2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2CompletedTreatmentPolycystic Kidney Diseases1
1, 2CompletedTreatmentRetinopathy, Diabetic1
1, 2CompletedTreatmentScleritis1
1, 2CompletedTreatmentSystemic Sclerosis1
1, 2CompletedTreatmentType 1 Diabetes Mellitus (T1DM)1
1, 2Not Yet RecruitingPreventionGraft Versus Host Disease (GVHD) / Lung Cancers1
1, 2RecruitingPreventionAdult Hodgkin Lymphoma / Adult Myelodysplastic Syndrome / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Hodgkin Lymphoma / Childhood Myelodysplastic Syndrome / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Myelofibrosis / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Non-Hodgkin's lymphoma1
1, 2RecruitingTreatmentAdenocarcinoma of the Lung / Extensive Stage Small Cell Lung Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Recurrent Small Cell Lung Carcinoma / Squamous Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1, 2RecruitingTreatmentCastration Levels of Testosterone / Hormone-Resistant Prostate Cancer / Metastatic Prostate Carcinoma / Prostate Carcinoma Metastatic in the Bone / PSA Progression / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
1, 2RecruitingTreatmentDesmoid Tumors1
1, 2RecruitingTreatmentGraft Versus Host Disease (GVHD) / Sickle Cells Disease / Thalassemias / Transplantation, Stem Cell1
1, 2RecruitingTreatmentHIV-1 Infections1
1, 2RecruitingTreatmentHyperinsulinism1
1, 2RecruitingTreatmentLeukemias / Lymphoma NOS1
1, 2RecruitingTreatmentMalignancies, Hematologic / Multiple Myeloma (MM)1
1, 2RecruitingTreatmentMalignant Peripheral Nerve Sheath Tumors (MPNST) / Sarcomas1
1, 2RecruitingTreatmentMetastatic Pancreatic Adenocarcinoma1
1, 2RecruitingTreatmentSickle Cells Disease2
1, 2RecruitingTreatmentType 1 Diabetes Mellitus (T1DM)1
1, 2TerminatedTreatmentAge-Related Macular Degeneration (ARMD) / Subfoveal Choroidal Neovascularization1
1, 2TerminatedTreatmentGraft Versus Host Disease (GVHD)1
1, 2TerminatedTreatmentMultiple Sclerosis (MS) / Multiple Sclerosis (MS) - Relapsing-remitting1
1, 2Unknown StatusTreatmentAplastic Anaemia (AA)1
1, 2Unknown StatusTreatmentEnd-Stage Renal Disease (ESRD) / Kidney Failure1
1, 2WithdrawnSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
1, 2WithdrawnTreatmentLung Cancers1
1, 2WithdrawnTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma1
2Active Not RecruitingPreventionGraft Versus Host Disease (GVHD)1
2Active Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3- / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Lymphoma / Childhood Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Burkitt Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Plasma Cell Myeloma / Secondary Myelodysplastic Syndromes / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Immunoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Burkitt Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Contiguous Immunoblastic Lymphoma / Stage II Adult Non-Contiguous Immunoblastic Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Burkitt Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Burkitt Lymphoma / Stage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma / Stage II Contiguous Adult Diffuse Small Cleaved Cell Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Grade 1 Contiguous Follicular Lymphoma / Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Stage II Grade 2 Contiguous Follicular Lymphoma / Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage II Non-Contiguous Adult Burkitt Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Small Cleaved Cell Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage II Small Lymphocytic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Burkitt Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Burkitt Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentCapillary Lymphatic Arterial Venous Malformations / Capillary Venous Lymphatic Malformation / Kaposiform Hemangioendotheliomas / Lymphangiectasia Syndromes / Microcystic Lymphatic Malformation / Mucocutaneous Lymphangiomatosis and Thrombocytopenia / PTEN Overgrowth Syndrome With Vascular Anomaly / Tufted Angioma / Venous Lymphatic Malformation1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Diffuse, Large B-Cell, Lymphoma / Lymphoma, Hodgkins / Lymphoma, Low-Grade / Lymphoma, Mantle-Cell / Small Lymphocytic Lymphoma (SLL) / T-Cell Lymphomas1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Precancerous/Nonmalignant Condition1
2Active Not RecruitingTreatmentEngraftment Syndrome / Graft Versus Host Disease (GVHD) / Renal Cell Carcinoma (RCC)1
2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD)2
2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS1
2Active Not RecruitingTreatmentLeukemias / Lymphoma NOS1
2Active Not RecruitingTreatmentNeurofibromatosis 21
2Active Not RecruitingTreatmentSickle Cells Disease2
2CompletedNot AvailableSturge - Weber Syndrome (SWS)1
2CompletedPreventionAcute Graft Versus Host Disease1
2CompletedPreventionAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myelogenous Leukemia (CML) / Graft Versus Host Disease (GVHD) / Hodgkins Disease (HD) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL)1
2CompletedPreventionAcute Lymphoblastic Leukaemias (ALL) / Hodgkins Disease (HD) / Malignancies, Hematologic / Myelodysplastic Syndrome / Myelogenous Leukemia / Non-Hodgkin's Lymphoma (NHL)1
2CompletedPreventionBlood and Marrow Transplant (BMT) / Leukemias / Non-Hodgkin's Lymphoma (NHL)1
2CompletedPreventionImmunosuppression / Kidney Failure,Chronic / Transplantation, Kidney1
2CompletedPreventionType 1 Diabetes Mellitus (T1DM)1
2CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Infection NOS / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Precancerous Conditions / Secondary Myelofibrosis / Small Intestine Cancer1
2CompletedSupportive CareGraft Versus Host Disease (GVHD)1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2CompletedTreatmentAcute Myeloid Leukaemias (AML)1
2CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
2CompletedTreatmentAge-Related Macular Degeneration (ARMD)1
2CompletedTreatmentAge-Related Macular Degeneration (ARMD) / Subfoveal Choroidal Neovascularization1
2CompletedTreatmentAngiofibromas / Tuberous Sclerosis1
2CompletedTreatmentAplastic Anaemia (AA)1
2CompletedTreatmentAutism / Self-injury / Tuberous Sclerosis Complex (TSC)1
2CompletedTreatmentBlood and Marrow Transplant (BMT) / Graft Versus Host Disease (GVHD)1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentCowden's Disease / Hamartoma Syndrome, Multiple1
2CompletedTreatmentDiabetes Mellitus, Insulin-Dependent1
2CompletedTreatmentDiabetes Mellitus, Type 11
2CompletedTreatmentDiabetic Macular Edema (DME)1
2CompletedTreatmentDisorder Related to Renal Transplantation1
2CompletedTreatmentDry Eyes1
2CompletedTreatmentGlioblastomas / Gliosarcoma1
2CompletedTreatmentGlomerulonephritis, Membranous / Lupus Membranous Nepropathy1
2CompletedTreatmentGlomerulosclerosis, Focal1
2CompletedTreatmentGraft Versus Host Disease (GVHD)1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Malignancies, Hematologic1
2CompletedTreatmentH1N1 Pneumonia / Hypoxemia1
2CompletedTreatmentHepatocellular Carcinomas1
2CompletedTreatmentHodgkins Disease (HD) / Leukaemia, Lymphoblastic / Multiple Myeloma (MM) / Myelogenous Leukemia / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentHypoglycemia / Metabolic Diseases / Type 1 Diabetes Mellitus (T1DM)1
2CompletedTreatmentKidney Failure1
2CompletedTreatmentKidney, Polycystic1
2CompletedTreatmentLeukemias / Lymphoma NOS / Myelodysplastic Syndromes1
2CompletedTreatmentLymphangioleiomyomatosis / Tuberous Sclerosis1
2CompletedTreatmentNeurofibromatosis Type 11
2CompletedTreatmentOsteosarcomas1
2CompletedTreatmentPancreatic Cancers2
2CompletedTreatmentRenal Cell Carcinoma (RCC)1
2CompletedTreatmentSarcomas1
2CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
2CompletedTreatmentTransplantation, Kidney3
2CompletedTreatmentType 1 Diabetes Mellitus (T1DM)1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukemia/Lymphoma / Acute Myeloid Leukaemias (AML) / Bone Marrow Failure Syndromes / Burkitt's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Leukaemia, Acute / Leukemia, Prolymphocytic / Lymphoma, Hodgkins / Lymphoma, Large-Cell / Lymphoma, Mantle-Cell / Lymphoplasmacytic Lymphoma / Marginal Zone B-Cell Lymphoma / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Syndromes / Natural Killer Cell Malignancies / Small Lymphocytic Lymphoma (SLL)1
2RecruitingNot AvailableDepression1
2RecruitingBasic ScienceAging1
2RecruitingBasic ScienceCancer of Breast1
2RecruitingBasic ScienceRecurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2RecruitingPreventionAcute Leukemia in Remission / Chronic Myeloid Leukemia (CML) / Chronic Myelomonocytic Leukemia / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL) / Primary Myelofibrosis1
2RecruitingPreventionEnd Stage Renal Disease (ESRD) / Venous Stenosis1
2RecruitingPreventionGraft Versus Host Disease (GVHD)1
2RecruitingPreventionGraft Versus Host Disease (GVHD) / Hematological Malignancy1
2RecruitingSupportive CareChronic Graft Versus Host Disease / Oral Mucosal Disease Due to Graft-versus-host Disease1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma / Acute Myelogenous Leukaemia (AML) / Acute Undifferentiated Leukemia (AUL) / Chemotherapy-sensitive Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Myelodysplastic Syndromes (MDS)1
2RecruitingTreatmentAcute GVHD1
2RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Secondary Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia in Remission / Secondary Myelodysplastic Syndromes / Therapy-Related Myelodysplastic Syndrome1
2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia / Adult Acute Myeloid Leukemia / Adult Diffuse Large B-Cell Lymphoma / Adult Myelodysplastic Syndrome / Adult Non-Hodgkin's Lymphoma / Aggressive Non-Hodgkin Lymphoma / Childhood Acute Lymphoblastic Leukemia / Childhood Acute Myeloid Leukemia / Childhood Diffuse Large B -Cell Lymphoma / Childhood Myelodysplastic Syndrome / Childhood Non-Hodgkin's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Lymphocytic Leukemia in Remission / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Hematopoietic and Lymphoid Cell Neoplasm / Leukemia, Prolymphocytic / Mantle Cell Lymphoma (MCL) / Plasma Cell Myeloma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / De Novo Myelodysplastic Syndromes / Myelodysplastic Syndrome With Isolated Del(5q) / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia1
2RecruitingTreatmentAplastic Anaemia (AA) / Immunodeficiency Syndrome / Non-Cancer Diagnosis / Severe Aplastic Anemia (SAA)1
2RecruitingTreatmentArteriovenous Malformations / Arteriovenous Malformations (Stage II to IV)1
2RecruitingTreatmentCancers1
2RecruitingTreatmentCancers / Leukemias / Lymphoma NOS1
2RecruitingTreatmentChondrosarcoma, Mesenchymal / Conventional Chondrosarcoma / Dedifferentiated Chondrosarcoma / Myxoid Liposarcoma1
2RecruitingTreatmentCongenital Hemolytic Anemia / Congenital Hypoplastic Anemia1
2RecruitingTreatmentDiabetes Mellitus, Type 12
2RecruitingTreatmentEpidermolysis Bullosa Simplex / Epidermolysis Bullosa Simplex Kobner / Weber-Cockayne Syndrome2
2RecruitingTreatmentGenetics / Growth Disorders / PIK3CA-Related Overgrowth Spectrum (PROS)1
2RecruitingTreatmentHHV-8 / HIV Disease / Lymphoproliferative Disorders / Malignancies1
2RecruitingTreatmentHaemangioma-thrombocytopenia syndrome / Kaposiform Hemangioendothelioma (KHE) / Tufted Angioma1
2RecruitingTreatmentIn-stent Stenosis / Peripheral Pulmonary Stenosis1
2RecruitingTreatmentLeukemias / Lymphoma NOS / Myelodysplastic Syndromes / Myeloproliferative Disorders1
2RecruitingTreatmentNeuroblastoma Recurrent1
2RecruitingTreatmentPineoblastoma1
2RecruitingTreatmentRefractory and/or Relapsed Metastatic Solid Tumors1
2RecruitingTreatmentRelapsed / Recurrent Germ Cell Tumors1
2RecruitingTreatmentSegmental Overgrowth Disorders Due to PIK3CA1
2RecruitingTreatmentSevere Aplastic Anemia (SAA)1
2RecruitingTreatmentSickle Cells Disease1
2RecruitingTreatmentVascular Malformations1
2TerminatedPreventionAcute Leukemia in Remission / Leukemia, Myeloid, Accelerated-Phase / Leukemia, Myeloid, Chronic-Phase / Myelodysplastic Syndromes1
2TerminatedPreventionGraft Versus Host Disease (GVHD)1
2TerminatedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Lymphoproliferative Disorders / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2TerminatedTreatmentAge-Related Macular Degeneration (ARMD) / Subfoveal Choroidal Neovascularization1
2TerminatedTreatmentEnd-Stage Renal Disease (ESRD)1
2TerminatedTreatmentGeographic Atrophy1
2TerminatedTreatmentHematologic Diseases1
2TerminatedTreatmentHematological Malignancy / Leukemias / Lymphoma NOS / Myelodysplastic Syndrome1
2TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2TerminatedTreatmentRenal Transplant1
2TerminatedTreatmentSarcomas1
2TerminatedTreatmentSquamous Cell Skin Carcinoma1
2TerminatedTreatmentType 1 Diabetes Mellitus (T1DM)1
2Unknown StatusPreventionAcute Graft-Versus-Host Disease / Chronic Graft Versus Host Disease / Steroid Refractory Graft-Versus-Host Disease1
2Unknown StatusTreatmentLymphangioleiomyomatosis / Tuberous Sclerosis1
2Unknown StatusTreatmentNonmalignant Neoplasm1
2Unknown StatusTreatmentTransplantation, Liver1
2WithdrawnPreventionHematopoietic Stem Cell Transplant (HSCT) / Severe Combined Immunodeficiency / Transplacental Maternal Engraftment1
2WithdrawnTreatmentCutaneous T-Cell Lymphoma (CTCL)1
2WithdrawnTreatmentDiabetes Mellitus, Type I1
2, 3Active Not RecruitingTreatmentChronic Graft Versus Host Disease1
2, 3Active Not RecruitingTreatmentInclusion Body Myositis (IBM)1
2, 3Active Not RecruitingTreatmentTransplantation, Kidney1
2, 3CompletedTreatmentLiver Carcinoma1
2, 3RecruitingTreatmentCongenital Hypoplastic Anemia1
2, 3RecruitingTreatmentCrohn's Disease (CD)1
2, 3RecruitingTreatmentLiver Diseases1
2, 3RecruitingTreatmentSturge-Weber Syndrome1
2, 3TerminatedTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)2
2, 3TerminatedTreatmentHypertensive1
2, 3Unknown StatusTreatmentPolycystic Kidney Diseases1
2, 3WithdrawnTreatmentCarcinoma of the Prostate1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Aggressive Non-Hodgkin Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Diffuse Large B-Cell Lymphoma (DLBCL) / Hematopoietic and Lymphoid Cell Neoplasm / Indolent Non-Hodgkin's Lymphomas / Leukemia, Prolymphocytic / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Recurrent Chronic Lymphocytic Leukemia / Recurrent Plasma Cell Myeloma / Refractory Chronic Lymphocytic Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Hodgkin Lymphoma / Small Lymphocytic Lymphoma (SLL) / T-cell chronic lymphocytic leukaemia / Waldenstrom's Macroglobulinemia (WM)1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Graft Versus Host Disease (GVHD) / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentExudative Age Related Macular Degeneration1
3Active Not RecruitingTreatmentNon-Infectious Uveitis of the Posterior Segment of the Eye1
3CompletedNot AvailableGraft Versus Host Disease (GVHD) / Transplantation, Kidney1
3CompletedPreventionGraft Versus Host Disease (GVHD) / Survival1
3CompletedPreventionKidney Diseases1
3CompletedPreventionRenal Allograft Recipients1
3CompletedPreventionRenal Transplant1
3CompletedPreventionTransplantation, Renal1
3CompletedTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
3CompletedTreatmentBirt-Hogg-Dubé Syndrome1
3CompletedTreatmentCardiovascular Abnormalities1
3CompletedTreatmentDiabetes Mellitus, Type 11
3CompletedTreatmentEnd Stage Liver Diseases / Impaired Renal Function1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Kidney Failure1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Transplantation, Kidney1
3CompletedTreatmentHepatocellular Carcinomas1
3CompletedTreatmentLeukemia, Lymphocytic, Acute / Leukemia, Myelocytic, Acute / Leukemia,Myeloid, Chronic / Myelodysplastic Syndromes1
3CompletedTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentSkin Cancers / Transplantation, Kidney1
3CompletedTreatmentTransplantation, Kidney1
3CompletedTreatmentTransplantation, Renal2
3CompletedTreatmentType 1 Diabetes Mellitus (T1DM)1
3CompletedTreatmentUvea; Posterior, Disorder / Uveitis; Posterior, Disorder1
3Enrolling by InvitationNot AvailableIslet Transplantation / Type 1 Diabetes Mellitus (T1DM)1
3RecruitingPreventionArteriovenous Fistulas / Chronic Kidney Failure / Complication of Hemodialysis / Complication of Renal Dialysis / End Stage Kidney Disease / End Stage Renal Disease (ESRD) / ESRD / Vascular Access Complications1
3RecruitingTreatmentPolycystic Kidney, Type 1 Autosomal Dominant Disease / Polycystic Kidney, Type 2 Autosomal Dominant Disease1
3RecruitingTreatmentType 1 Diabetes Mellitus (T1DM)1
3RecruitingTreatmentVascular Malformations1
3TerminatedTreatmentAtherosclerosis / Kidney Failure1
3TerminatedTreatmentEnd-Stage Renal Disease (ESRD) / Transplantation, Kidney1
3TerminatedTreatmentOral Lichen Planus1
3TerminatedTreatmentTransplant, Kidney1
3TerminatedTreatmentTransplantation, Liver1
3Unknown StatusPreventionHepatocellular Carcinomas1
3Unknown StatusPreventionTransplantation, Kidney1
3Unknown StatusTreatmentLymphangioleiomyomatosis1
4Active Not RecruitingPreventionRenal Transplant Rejection1
4Active Not RecruitingTreatmentPancreas Transplantation / Transplantation, Kidney1
4CompletedNot AvailableChronic Kidney Failure / Graft Versus Host Disease (GVHD) / Transplantation, Kidney1
4CompletedNot AvailableFunction of Renal Transplant1
4CompletedHealth Services ResearchCoronary Artery Restenosis / Coronary Heart Disease (CHD)1
4CompletedPreventionAcute Graft Rejection / Delayed Graft Function1
4CompletedPreventionGraft Rejection / Kidney Failure1
4CompletedPreventionGraft Rejection / Renal Allograft Recipients / Renal Transplant / Transplant, Kidney1
4CompletedPreventionHepatitis C1
4CompletedPreventionSkin Neoplasms / Transplantation, Kidney1
4CompletedPreventionTransplantation, Kidney2
4CompletedTreatmentAdult Primary Kidney Transplantation1
4CompletedTreatmentAgeing / Graft Rejection / Kidney Failure1
4CompletedTreatmentChronic Kidney Disease (CKD) / Transplantation, Kidney1
4CompletedTreatmentComparative Study / Immunosuppressive Agents1
4CompletedTreatmentCoronary Artery Restenosis1
4CompletedTreatmentDisorder Related to Renal Transplantation / Infections, Cytomegalovirus1
4CompletedTreatmentEnd-Stage Renal Disease (ESRD)1
4CompletedTreatmentGraft Rejection / Kidney Failure / Transplant, Kidney1
4CompletedTreatmentGraft Rejection / Kidney Failure / Transplantation, Kidney1
4CompletedTreatmentGraft Versus Host Disease (GVHD) / Kidney Failure2
4CompletedTreatmentKidney Diseases1
4CompletedTreatmentKidney Diseases / Kidney Failure1
4CompletedTreatmentPrimary Renal Allograft1
4CompletedTreatmentRenal Angiomyolipomas1
4CompletedTreatmentRenal Transplant1
4CompletedTreatmentTransplant, Kidney2
4CompletedTreatmentTransplantation, Kidney6
4CompletedTreatmentTransplantation, Liver1
4CompletedTreatmentTransplantation, Renal1
4CompletedTreatmentInflammatory processes1
4Not Yet RecruitingTreatmentCCR5 / HIV Disease / HIV Reservoir / Transplant, Kidney1
4RecruitingPreventionInfections, Cytomegalovirus1
4RecruitingTreatmentTransplantation, Kidney1
4TerminatedPreventionRenal Transplant Patients at High-risk for Skin Cancer1
4TerminatedPreventionSkin Cancers / Transplantation, Kidney1
4TerminatedTreatmentKidney Transplant Failure and Rejection1
4Unknown StatusPreventionImmunosuppression / Transplantation, Kidney / Transplantations2
4Unknown StatusTreatmentChronic Allograft Nephropathy (CAN) / Glomerular Filtration Rate (GFR)1
4Unknown StatusTreatmentDelayed Graft Function / Slow Graft Function-defined at Creatinine >= 3.0 by Post-op Day 5 Without Requiring Dialysis / Transplant, Kidney1
4Unknown StatusTreatmentEnd Stage Renal Disease (ESRD) / Transplantation, Kidney1
4Unknown StatusTreatmentGraft Rejection / Kidney Diseases1
4Unknown StatusTreatmentImmunosuppression / Interstitial Fibrosis (IF) / Kidney Failure,Chronic / Transplantations1
4Unknown StatusTreatmentTransplant, Kidney1
4Unknown StatusTreatmentTransplantation, Kidney2
4WithdrawnNot AvailableTransplantation, Kidney1
4WithdrawnTreatmentKidney Graft Dysfunction1
4WithdrawnTreatmentLiving Donor Kidney Transplants Patients1
Not AvailableActive Not RecruitingNot AvailableImmune Thrombocytopenia1
Not AvailableActive Not RecruitingPreventionRenal Failure1
Not AvailableActive Not RecruitingTreatmentDiffuse Parenchymal Lung Diseases / Idiopathic Pulmonary Fibrosis (IPF) / Interstitial Lung Disease (ILD)1
Not AvailableActive Not RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
Not AvailableCompletedNot AvailableADPKD1
Not AvailableCompletedNot AvailableImmune Thrombocytopenic Purpura ( ITP )1
Not AvailableCompletedNot AvailableTransplantation, Kidney1
Not AvailableCompletedNot AvailableTransplantation, Renal1
Not AvailableCompletedNot AvailableTransplantations1
Not AvailableCompletedBasic ScienceSarcopenia1
Not AvailableCompletedPreventionAbsence; Kidney1
Not AvailableCompletedPreventionRenal Transplant2
Not AvailableCompletedScreeningTransplantation, Kidney1
Not AvailableCompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
Not AvailableCompletedTreatmentAML1
Not AvailableCompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T-Cell Leukemia/Lymphoma / Burkitt's Lymphoma / Lymphoid Malignancies (New or Relapsed) / Lymphoma, Lymphoblastic / Mantle Cell Lymphoma (MCL)1
Not AvailableCompletedTreatmentEnd-Stage Renal Disease (ESRD)1
Not AvailableCompletedTreatmentPosttraumatic Stress Disorders1
Not AvailableNo Longer AvailableNot AvailableDiabetes Mellitus, Type 11
Not AvailableNo Longer AvailableNot AvailableType 1 Diabetes Mellitus (T1DM)1
Not AvailableNot Yet RecruitingTreatmentRefractory Solid Tumors1
Not AvailableRecruitingNot AvailableLymphangioleiomyomatosis1
Not AvailableRecruitingDiagnosticAcute Rejection of Liver Transplant / Effects of Immunosuppressant Therapy1
Not AvailableRecruitingSupportive CarePrimary Myelofibrosis / Secondary Myelofibrosis1
Not AvailableRecruitingTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Untreated Adult Acute Myeloid Leukemia1
Not AvailableRecruitingTreatmentHemoglobinopathies / Sickle Cells Disease1
Not AvailableRecruitingTreatmentMyelodysplastic Syndrome / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia1
Not AvailableRecruitingTreatmentTumors, Solid1
Not AvailableTerminatedNot AvailableTransplantation, Renal1
Not AvailableTerminatedTreatmentPolycystic Liver Disease (PLD)1
Not AvailableTerminatedTreatmentPort-wine Stains (PWS)1
Not AvailableTerminatedTreatmentRecurrent Adult Lymphoblastic Lymphoma / Refractory Acute Lymphoblastic Leukemia / Refractory Lymphoblastic Lymphoma / Relapsed Lymphoblastic Leukemia1
Not AvailableUnknown StatusNot AvailableAcute Rejection of Renal Transplant1
Not AvailableUnknown StatusTreatmentCarcinoma of the Prostate1
Not AvailableWithdrawnPreventionCardiac Allograft Vasculopathy1
Pharmacoeconomics
Manufacturers
  • Wyeth pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
SolutionOral1 mg/ml
TabletOral1.0 mg
TabletOral2 mg
TabletOral5 mg
Tablet, coatedOral0.5 mg
Tablet, coatedOral1 mg
Tablet, coatedOral2 mg
Tablet, sugar coatedOral.5 mg/1
Tablet, sugar coatedOral1 mg/1
Tablet, sugar coatedOral2 mg/1
SolutionOral1.0 mg
TabletOral1 mg/1
TabletOral2 mg/1
Tablet, film coatedOral.5 mg/1
Prices
Unit descriptionCostUnit
Rapamune 2 mg tablet20.59USD tablet
Rapamune 1 mg/ml Solution12.19USD ml
Rapamune 1 mg tablet11.95USD tablet
Rapamune 0.5 mg tablet5.86USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2103571 No2003-04-292012-02-21Canada
CA2293793 No2006-07-112018-06-11Canada
US5212155 No1993-05-182010-05-18Us
US5989591 Yes1998-09-112018-09-11Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00173 mg/mLALOGPS
logP4.85ALOGPS
logP7.45ChemAxon
logS-5.7ALOGPS
pKa (Strongest Acidic)9.96ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area195.43 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity250.66 m3·mol-1ChemAxon
Polarizability100.46 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7841
Blood Brain Barrier-0.9599
Caco-2 permeable-0.6341
P-glycoprotein substrateSubstrate0.8052
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.8021
Renal organic cation transporterNon-inhibitor0.8116
CYP450 2C9 substrateNon-substrate0.878
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateSubstrate0.7776
CYP450 1A2 substrateNon-inhibitor0.9007
CYP450 2C9 inhibitorNon-inhibitor0.9125
CYP450 2D6 inhibitorNon-inhibitor0.9414
CYP450 2C19 inhibitorNon-inhibitor0.9158
CYP450 3A4 inhibitorNon-inhibitor0.9333
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9742
Ames testNon AMES toxic0.6617
CarcinogenicityNon-carcinogens0.9546
BiodegradationNot ready biodegradable0.9593
Rat acute toxicity2.8689 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9831
hERG inhibition (predictor II)Non-inhibitor0.8443
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as macrolide lactams. These are cyclic polyketides containing both a cyclic amide and a cyclic ester group.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassMacrolide lactams
Sub ClassNot Available
Direct ParentMacrolide lactams
Alternative Parents
Substituents
  • Macrolide lactam
  • Alpha-amino acid ester
  • Macrolide
  • Alpha-amino acid or derivatives
  • Cyclohexanol
  • Oxane
  • Piperidine
  • Cyclic alcohol
  • Tertiary carboxylic acid amide
  • Cyclic ketone
  • Secondary alcohol
  • Carboxamide group
  • Carboxylic acid ester
  • Hemiacetal
  • Ketone
  • Lactam
  • Lactone
  • Organoheterocyclic compound
  • Azacycle
  • Carboxylic acid derivative
  • Oxacycle
  • Dialkyl ether
  • Ether
  • Monocarboxylic acid or derivatives
  • Organopnictogen compound
  • Alcohol
  • Organic oxygen compound
  • Carbonyl group
  • Organooxygen compound
  • Organonitrogen compound
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Tfiiic-class transcription factor binding
Specific Function:
Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activ...
Gene Name:
MTOR
Uniprot ID:
P42345
Molecular Weight:
288889.05 Da
References
  1. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N: Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2010 Mar;1804(3):433-9. doi: 10.1016/j.bbapap.2009.12.001. Epub 2009 Dec 11. [PubMed:20005306 ]
  2. Shuuin T, Karashima H: [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma]. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9. [PubMed:19620795 ]
  3. Sehgal SN: Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003 May;35(3 Suppl):7S-14S. [PubMed:12742462 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
other
General Function:
Type i transforming growth factor beta receptor binding
Specific Function:
Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. Recruites SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. May modulate the RYR1 calcium channel activity. PPIases accelerate the folding of proteins....
Gene Name:
FKBP1A
Uniprot ID:
P62942
Molecular Weight:
11950.665 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Sehgal SN: Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003 May;35(3 Suppl):7S-14S. [PubMed:12742462 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
other/unknown
General Function:
Ligand-dependent nuclear receptor transcription coactivator activity
Specific Function:
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name:
FGF2
Uniprot ID:
P09038
Molecular Weight:
30769.715 Da
References
  1. Sehgal SN: Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003 May;35(3 Suppl):7S-14S. [PubMed:12742462 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764 ]
  2. Wacher VJ, Silverman JA, Wong S, Tran-Tau P, Chan AO, Chai A, Yu XQ, O'Mahony D, Ramtoola Z: Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. J Pharmacol Exp Ther. 2002 Oct;303(1):308-13. [PubMed:12235265 ]
  3. Arceci RJ, Stieglitz K, Bierer BE: Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood. 1992 Sep 15;80(6):1528-36. [PubMed:1381629 ]
  4. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Fehrenbach T, Cui Y, Faulstich H, Keppler D: Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):415-20. Epub 2003 Oct 3. [PubMed:14530907 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Monovalent cation:proton antiporter activity
Specific Function:
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, ganciclovir and also the zwitterionic cephalosporin, cephalexin and cephradin. Seems to also play a role in the uptake of oxaliplatin (a new platinum anticancer agent). Able to transport...
Gene Name:
SLC47A1
Uniprot ID:
Q96FL8
Molecular Weight:
61921.585 Da
References
  1. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB: Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005. doi: 10.1152/ajprenal.00431.2009. Epub 2010 Jan 6. [PubMed:20053795 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on March 29, 2017 04:07